报告题目 | Innovative Strategies in Organic and Medicinal Chemistry: Accelerating Drug Discovery and Chemical Biology |
报告人 | Dr. Mateusz Plesniak,Associate Principal Scientist |
报告人单位 | AstraZeneca（阿斯利康制药有限公司） |
报告时间 | 2025年2月28日（星期五）10:00 |
报告地点 | 环境资源楼939会议室 |
主办单位 | 精准智能化学全国重点实验室 |
In the rapidly evolving fields of organic and medicinal chemistry, innovative synthetic methodologies play a crucial role in advancing chemical biology and drug discovery. The first featured project introduces an advanced methodology for the rapid screening and hit finding for proteolysis targeting chimeras (PROTACs). By employing a nano-mole scale amide bond formation followed by direct screening from non-purified reaction mixtures, rapid SAR exploration is facilitated with minimal material requirements thus enhancing efficiency and sustainability in PROTAC hit finding. The second project presents a scalable photoredox catalysis strategy for synthesizing sp3-rich alkyl sulfonyl fluorides from simple building blocks. This mild and efficient process, leveraging halogen atom transfer (XAT), facilitates quick access to valuable derivatives and demonstrates scalability through continuous reactor technology. | |
报告人简介 | Dr Mateusz Plesniak started his scientific journey with an Engineering and Master's degree at the Silesian University of Technology in Poland. He then followed with a PhD in radical chemistry with Prof. David Procter at the University of Manchester in the United Kingdom, where he was working on Samarium(II) radical cyclizations for the synthesis of complex scaffolds. He then pursued postdoctoral research in total synthesis with Prof. Alois Fürstner at the Max Planck Institute for Coal Research in Mülheim, Germany. In 2019, Mateusz joined the pharmaceutical company AstraZeneca in Gothenburg, Sweden, where he worked in Synthetic and Medicinal Chemistry, first as a Senior Research Scientist and since 2023 as an Associate Principal Scientist. Apart from working on drug discovery projects in cardiovascular, renal and metabolism area, his research interest covers the interface of synthetic and medicinal chemistry, featuring high-throughput synthesis and covalent warheads. During his time at AstraZeneca, Mateusz was awarded a Science Catalyst 100 thousands dollars grant to develop high-throughput synthesis and screening methodology and also he is recipient of AstraZeneca Postdoctoral grant for the synthesis of covalent warheads using photoredox chemistry. |
